Found: 17
Select item for more details and to access through your institution.
Response to: Interference of daratumumab on the serum protein electrophoresis.
- Published in:
- Clinical Chemistry & Laboratory Medicine, 2017, v. 55, n. 2, p. e29, doi. 10.1515/cclm-2016-1026
- By:
- Publication type:
- Article
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
- Published in:
- Frontiers in Immunology, 2018, p. N.PAG, doi. 10.3389/fimmu.2018.02134
- By:
- Publication type:
- Article
Risk factors for hematological malignancy in polyneuropathy associated with monoclonal gammopathy.
- Published in:
- 2001
- By:
- Publication type:
- journal article
High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
- Published in:
- Cytometry. Part A, 2019, v. 95, n. 3, p. 279, doi. 10.1002/cyto.a.23693
- By:
- Publication type:
- Article
Acute and chronic renal artery stenosis.
- Published in:
- European Heart Journal, 2010, v. 31, n. 1, p. 14, doi. 10.1093/eurheartj/ehp455
- By:
- Publication type:
- Article
Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 10, p. 665, doi. 10.1016/j.clml.2024.05.003
- By:
- Publication type:
- Article
Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 6, p. 350, doi. 10.1016/j.clml.2024.03.005
- By:
- Publication type:
- Article
Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 6, p. 413, doi. 10.1016/j.clml.2023.03.009
- By:
- Publication type:
- Article
P-203: EXCALIBER: a phase 3 study comparing iberdomide, daratumumab, and dexamethasone (IberDd) with daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S150, doi. 10.1016/S2152-2650(21)02330-2
- By:
- Publication type:
- Article
P-155: Incidence, mitigation, and management of neurologic adverse events in CARTITUDE-2, a phase 2 study of ciltacabtagene autoleucel (cilta-cel) in patients with Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S120, doi. 10.1016/S2152-2650(21)02282-5
- By:
- Publication type:
- Article
OAB-025: Talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D)×CD3 bispecific antibody, in relapsed/refractory multiple myeloma (RRMM): Updated results of a phase 1, first-in-human study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S16, doi. 10.1016/S2152-2650(21)02099-1
- By:
- Publication type:
- Article
OAB-013: Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S9, doi. 10.1016/S2152-2650(21)02087-5
- By:
- Publication type:
- Article
OAB-008: Identification of high-risk Multiple Myeloma with a plasma cell Leukemia-like transcriptomic profile.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S6, doi. 10.1016/S2152-2650(21)02082-6
- By:
- Publication type:
- Article
MM-112: Incidence, Mitigation, and Management of Neurologic Adverse Events in the CARTITUDE-2 Study of Patients with Multiple Myeloma Treated with Ciltacabtagene Autoleucel (Cilta-Cel).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S421, doi. 10.1016/S2152-2650(21)01945-5
- By:
- Publication type:
- Article
Poster: MM-112: Incidence, Mitigation, and Management of Neurologic Adverse Events in the CARTITUDE-2 Study of Patients with Multiple Myeloma Treated with Ciltacabtagene Autoleucel (Cilta-Cel).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S249, doi. 10.1016/S2152-2650(21)01568-8
- By:
- Publication type:
- Article
Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Waldenström macroglobulinemia presenting as nephrotic syndrome: Renal heavy and light chain amyloidosis.
- Published in:
- EJHaem, 2022, v. 3, n. 2, p. 565, doi. 10.1002/jha2.424
- By:
- Publication type:
- Article